-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$3.630.55% Upside
ProQR Therapeutics N.V. Frequently Asked Questions
-
What analysts cover ProQR Therapeutics N.V.?
ProQR Therapeutics N.V. has been rated by research analysts at Loop Capital Markets, Raymond James, Cantor Fitzgerald, Chardan Capital in the past 90 days.